Serous Papillary Endometrial Cancer Clinical Trial
Official title:
Expression of the P16 Protein in Serous Papillary Endometrial Cancer, and Its Clinical and Prognostic Significance
P16 is a tumor suppressor protein implicated in serous papillary endometrial carcinoma.
Evidence from previous trials indicates that it may be used as a diagnostic biomarker
distinguishing this disease from endometrioid endometrial cancer. Additional evidence points
to its prognostic value.
The current study will evaluate p16 both as a diagnostic tool for serous papillary
endometrial cancer and as a prognostic biomarker.
following anonymization, histology blocks will be microtomed and stained for P16 and P53
proteins.
Blocks from endometrioid endometrial cancer will be used as a control group.
n/a
Observational Model: Case Control, Time Perspective: Retrospective